Biff #SARSisAirborne 🍉 Profile picture
Jan 10 1 tweets 2 min read Read on X
📢Novavax / Nuvaxovid availability update

As you’ve probably heard, most doses (Lot Nos. 315MF001C and 6315MF002C) expired on December 31st.

There is still a batch in circulation with an expiry date of February 28th.

We’re still unsure if Novavax/Sanofi will be releasing any more batches for the spring after that.

If you’re looking for a pharmacy that has restocked following the Dec. 31st expiry - Anecdotally, I’ve heard more success coming from CVS locations compared to other chains.

Reminders, when you’re calling any pharmacy to check for availability:

1. Ask if they’re willing to check the fridge, as new stock will oftentimes go unnoticed by staff.

2. The product is now most commonly being referred to as “Nuvaxovid”, following Novavax’s BLA approval in May 2025. Most people will continue to use the names interchangeably, so make sure that your pharmacy understands that Novavax and Nuvaxovid are the same thing and they’re not confused by the naming (or by the similarity to Moderna’s “Spikevax”). Alternatively, if it works better for them, you can provide them with the National Drug Code (NDC) so they can look up the product in their system. The Nuvaxovid NDC is 80631-207-10 (cartons) or 80631-207-01 (single syringes).

3. Nuvaxovid is still available to order through distributors and through Sanofi’s own portal, VaccineShoppe (vaccineshoppe.com/vsh/en/USD/pro…). Especially let your small, local, and independent pharmacies know if you would like them to place an order. Employees at large pharmacy chains typically lack the authority to place an order for their own store, but still communicate your desire - they can pass the information up the chain, which is important right now as vaccine contracting for the 2026-2027 season will already be getting underway within the next couple of weeks/months.

As always, when you show up for an appointment, it’s always best practice to both verbally and visually confirm that you’re actually receiving Novavax. Unfortunately, pharmacies oftentimes make errors, and they’re going to be more common during product rollout periods, periods of increased respiratory illness activity (now), and periods with stock inconsistencies (now, as a result of the Dec. 31st expiry)Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Biff #SARSisAirborne 🍉

Biff #SARSisAirborne 🍉 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Biff234523

Sep 7, 2025
💉🧵 Why Novavax is the better COVID-19 vaccine

While we *still* wait for Novavax to roll out, since today is Sunday and pharmacies & customer support lines are closed, I’m taking a step back to a very basic concept and giving a reminder of WHY we’re all waiting for Novavax in the first place. And why nobody should be considering rushing out to get mRNA right now.

Some forget in the midst of all the panic, and some people looking at us “holdouts” from the outside may still be confused about why anyone would ever bother to wait for Novavax in the first place.

This will also be the topic of the next article that @DonEford releases, so keep an eye out for a much more in-depth and scientific analysis than this thread will offer.

You often hear Novavax discussed as a “traditional protein-based vaccine”, which makes it similar to vaccines like Influenza, Hepatitis B, Tdap, & HPV. This is true, which is a testament to Novavax’s safety profile, but it’s not an entirely accurate characterization.

While protein is traditional, Novavax also makes use of cutting-edge technology in two distinct ways when compared to other vaccines.

Technology 1: Sf9 cells from the Fall Armyworm moth.

This is what makes it possible to produce a high-quality protein vaccine targeting a respiratory virus in the first place. Many vaccines, like traditional flu shots, are “inactivated virus vaccines”. These products are made by growing the virus in eggs, and then inactivating it to include in the finished shot. In that process, adaptation becomes an issue. The virus is required to adapt to grow in the eggs, which means the finished product may contain antigen that is clinically significantly different from the antigen seen in the virus actually circulating in the real world.

Novavax uses a completely different process, where they skip the step of needing to “grow” the entire virus. Instead, they take the gene for the SARS2 spike protein, insert it into a baculovirus, which then infects Sf9 insect cells that come from the fall armyworm moth. Those cells then produce pure spike protein that is used in the finished product. This allows them to produce antigen that is much more closely matched to circulating viruses, just like mRNA, while still using the more traditional protein base.

Technology 2: Matrix-M adjuvant.

Matrix-M, which is a saponin-based adjuvant developed by Novavax, is the star of the entire show here. Saponins are natural plant compounds that form soap-like foams in water. Matrix-M specifically comes from the bark of the Quillaja saponaria tree, aka “soapbark tree.” An adjuvant is a substance oftentimes added to vaccines to enhance the immune response to the antigen, and Matrix-M is a next-gen adjuvant that is showing an amazing amount of promise. For example, it’s now being used in a childhood malaria vaccine in Africa, and providing 70% efficacy, compared to the 35% efficacy from previous vaccines! In addition to driving strong antibody responses (B cells) which is pretty much the only thing that older adjuvants do well, Matrix-M also elicits a strong cellular response and memory among T Cells. The Matrix-M mechanism of action is illustrated below.

Okay, cool, thanks to the soapbark tree and the fall armyworm moth. Nature is great! But how do these technologies play out in the real world when it comes to the COVID vaccine?
Do we have evidence of them *actually* providing us particularly noteworthy protection?

Yes! The following categories and studies are all proof of that, and are just a selected handful out of many dozens of studies that prove why Novavax is the best vaccine choice.

There are 5 main categories (in addition to the benefit of the JN.1 antigen target, which I’ve already described in the past) that illustrate why Novavax is the best choice:

1. Less waning/better infection protection

2. “Universal-like” variant coverage

3. Better mucosal protection

4. Less side effects

5. No IgG4 class switching

1/4Image
🔵Novavax wanes less over time, and provides meaningful protection against actual infection.

Study 1:
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial: sciencedirect.com/science/articl…

This study found that priming series of Novavax induced persistent immune responses up to 1 year after the second dose.

Study 2:
Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea: sciencedirect.com/science/articl…

Novavax performed better than the Pfizer vaccine for preventing lab-confirmed SARS-CoV-2 infection. Novavax has an aHR of 0.78 after the third dose and 0.86 after the fourth dose, meaning it was 14% to 22% better at preventing infection.

Study 3:
Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents: pubmed.ncbi.nlm.nih.gov/40865116/

This is the same type of study as the previous one, except this time, it was conducted in an adolescent population. Once again, it found that Novavax performed better than the Pfizer vaccine. Novavax had an aHR of 0.57 for a priming series and 0.68 for a booster dose, meaning it was 32% to 43% better at preventing infection:

Study 4:
Characteristics and Outcomes for Recipients of NVX-CoV2373: A Real-World Retrospective Study in Germany: mdpi.com/2076-393X/12/4…

Within the 10 months after receiving Novavax, there was a 95% reduction in the amount of doctor’s visits associated with COVID-19 diagnosis.

🔵Additional Novavax doses shrink the antigenic range. This means that the breadth of protective antibodies, against additional and future variants, increases.

Study:
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373: nejm.org/doi/full/10.10…

This study found that “Boosting with Novavax resulted in enhanced cross-reactive immunity to SARS-CoV-2 variants, a decreased gap between immune recognition of the variants and the ancestral strain, and the induction of a potentially more universal-like response against SARS-CoV-2 variants.”

🔵Novavax provides better protection in the upper respiratory tract, which is extremely important when trying to avoid infections in general, long covid, and translocation to the brain & lower respiratory tract:

Study 1:
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates: pmc.ncbi.nlm.nih.gov/articles/PMC10…

Novavax blunted virus replication and showed a significant reduction in viral load in the airway early post-infection, at days 2 and 4. Conversely, the mRNA shot offered only limited protection at days 2 and 4, and took longer to “catch up”.

Study 2:
Detection of anti–SARS-CoV-2 mucosal IgA in clinical saliva samples after a dose of Novavax COVID-19 vaccine: medrxiv.org/content/10.110…

Salivary samples collected 28 days after vaccination showed a significant increase in anti-SARS-CoV-2 spike antibodies.
For this study, it’s notable Novavax actually had to develop their own test to establish a way to test for mucosal IgA, because we didn't have one before, because we never needed one, because no vaccines in the past have even came close to providing this level of mucosal immunity. Let that sink in.

2/4
🔵Lower reactogenicity (less side effects):

Study 1:
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study: mdpi.com/2076-393X/12/1…

This study found lower rates of local and systemic reactogenicity symptoms reported for Novavax compared to mRNA. Additionally, a larger proportion of reported events were grade 1 (mild) for Novavax when compared to mRNA.

Conclusion: “Following receipt of NVX-CoV2373 than an mRNA vaccine. The data suggest that Novavax booster recipients trended toward being less impaired overall than recipients of an mRNA booster.”

Study 2 (SHIELD-Utah study):
mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and the Relationship to Productivity for Healthcare Workers and First Responders: medrxiv.org/content/10.110…

Workers who received Novavax were 60% less likely to report a systemic side effect (like fatigue) and 90% less likely to report a local side effect (like injection site pain). Novavax recipients lost 50% fewer work hours and 66% fewer productive hours.

🔵Higher IgG3 antibodies, lower IgG4 antibodies:

Study:
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines: journalofinfection.com/article/S0163-…

Repeated mRNA vaccination was associated with an increase in Spike-specific IgG4. By contrast, IgG4 class switch was not observed following four doses of Novavax. SARS-CoV-2 specific IgG3, an IgG subclass known to induce potent neutralization and Fc functions, was higher after Novavax (>10X Vs. mRNA). There’s a whole lot to unpack here, but the basic idea is that igG4 class switch results in lower neutralizing antibodies and immune tolerance to SARS2 spike.

3/4
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(